Literature DB >> 7969358

Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs.

T V Perneger1, P K Whelton, M J Klag.   

Abstract

BACKGROUND: People who take analgesic drugs frequently may be at increased risk of end-stage renal disease (ESRD), but the extent of this risk remains unclear.
METHODS: We studied 716 patients treated for ESRD and 361 control subjects of similar age from Maryland, Virginia, West Virginia, and Washington, D.C. The study participants were interviewed by telephone about their past use of medications containing acetaminophen, aspirin, and other nonsteroidal antiinflammatory drugs (NSAIDs). For each analgesic drug, the average use (in pills per year) and the cumulative intake (in pills) were examined for any association with ESRD.
RESULTS: Heavier acetaminophen use was associated with an increased risk of ESRD in a dose-dependent fashion. When persons who took an average of 0 to 104 pills per year were used for reference, the odds ratio of ESRD was 1.4 (95 percent confidence interval, 0.8 to 2.4) for those who took 105 to 365 pills per year and 2.1 (95 percent confidence interval, 1.1 to 3.7) for those who took 366 or more pills per year, after adjustment for race, sex, age, and intake of other analgesic drugs. When persons who had taken fewer than 1000 pills containing acetaminophen in their lifetime were used for reference, the odds ratio was 2.0 (95 percent confidence interval, 1.3 to 3.2) for those who had taken 1000 to 4999 pills and 2.4 (95 percent confidence interval, 1.2 to 4.8) for those who had taken 5000 or more pills. Approximately 8 to 10 percent of the overall incidence of ESRD was attributable to acetaminophen use. A cumulative dose of 5000 or more pills containing NSAIDs was also associated with an increased odds of ESRD (odds ratio, 8.8), but the use of aspirin was not.
CONCLUSIONS: People who often take acetaminophen or NSAIDs have an increased risk of ESRD, but not those who often take aspirin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969358     DOI: 10.1056/NEJM199412223312502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  76 in total

Review 1.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Race and kidney disease: the scope of the problem.

Authors:  Keith C Norris; Lawrence Y Agodoa
Journal:  J Natl Med Assoc       Date:  2002-08       Impact factor: 1.798

Review 3.  Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs.

Authors:  Paul Dieppe; Christopher Bartlett; Peter Davey; Lesley Doyal; Shah Ebrahim
Journal:  BMJ       Date:  2004-07-03

4.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

Review 5.  Paracetamol: new vistas of an old drug.

Authors:  Alfio Bertolini; Anna Ferrari; Alessandra Ottani; Simona Guerzoni; Raffaella Tacchi; Sheila Leone
Journal:  CNS Drug Rev       Date:  2006 Fall-Winter

Review 6.  End stage renal disease.

Authors:  Yoshio N Hall; Glenn M Chertow
Journal:  BMJ Clin Evid       Date:  2007-10-17

7.  Non-steroidal anti-inflammatory drugs in elderly people. Gastrointestinal bleeding is common.

Authors:  J R Laporte; X Vidal; X Carne
Journal:  BMJ       Date:  1995-08-05

Review 8.  End-stage renal disease.

Authors:  Maaz Ahmed Abbasi; Glenn M Chertow; Yoshio N Hall
Journal:  BMJ Clin Evid       Date:  2010-07-19

Review 9.  Tenidap: not just another NSAID?

Authors:  J M Canvin; R Madhok
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

Review 10.  Analgesic nephropathy: is it caused by multi-analgesic abuse or single substance use?

Authors:  M M Elseviers; M E De Broe
Journal:  Drug Saf       Date:  1999-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.